293 related articles for article (PubMed ID: 21353178)
1. The backbone of progress--preclinical studies and innovations with zoledronic acid.
Green JR; Guenther A
Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S3-S12. PubMed ID: 21353178
[TBL] [Abstract][Full Text] [Related]
2. New role for an established drug? Bisphosphonates as potential anticancer agents.
Koul HK; Koul S; Meacham RB
Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):111-9. PubMed ID: 21876554
[TBL] [Abstract][Full Text] [Related]
3. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
Terpos E; Dimopoulos MA; Berenson J
Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S13-23. PubMed ID: 21353176
[TBL] [Abstract][Full Text] [Related]
4. Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?
Morgan GJ
Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S24-30. PubMed ID: 21353177
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid: a framework of emerging anticancer evidence throughout the cancer continuum.
Terpos E
Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S1-2. PubMed ID: 21353175
[No Abstract] [Full Text] [Related]
6. Antitumor effects of bisphosphonates.
Green JR
Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584
[TBL] [Abstract][Full Text] [Related]
7. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.
Guenther A; Gordon S; Tiemann M; Burger R; Bakker F; Green JR; Baum W; Roelofs AJ; Rogers MJ; Gramatzki M
Int J Cancer; 2010 Jan; 126(1):239-46. PubMed ID: 19621390
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates: preclinical review.
Green JR
Oncologist; 2004; 9 Suppl 4():3-13. PubMed ID: 15459425
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumour activity of zoledronic acid.
Clézardin P
Cancer Treat Rev; 2005; 31 Suppl 3():1-8. PubMed ID: 16225995
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates in preclinical bone oncology.
Clézardin P; Benzaïd I; Croucher PI
Bone; 2011 Jul; 49(1):66-70. PubMed ID: 21145441
[TBL] [Abstract][Full Text] [Related]
12. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
[TBL] [Abstract][Full Text] [Related]
13. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
Stresing V; Fournier PG; Bellahcène A; Benzaïd I; Mönkkönen H; Colombel M; Ebetino FH; Castronovo V; Clézardin P
Bone; 2011 Feb; 48(2):259-66. PubMed ID: 20920623
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates as anticancer therapy for early breast cancer.
Mahtani R; Jahanzeb M
Clin Breast Cancer; 2010 Oct; 10(5):359-66. PubMed ID: 20920980
[TBL] [Abstract][Full Text] [Related]
15. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice.
Ory B; Heymann MF; Kamijo A; Gouin F; Heymann D; Redini F
Cancer; 2005 Dec; 104(11):2522-9. PubMed ID: 16270320
[TBL] [Abstract][Full Text] [Related]
17. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid: past, present and future roles in cancer treatment.
Saad F
Future Oncol; 2005 Apr; 1(2):149-59. PubMed ID: 16555985
[TBL] [Abstract][Full Text] [Related]
19. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class.
Clézardin P
Bone; 2011 Jan; 48(1):71-9. PubMed ID: 20655399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
